Clinical Scorecard: Migraine therapy in congenital heart disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Migraine with patent foramen ovale |
| Key Mechanisms | Antithrombotic agents (aspirin, clopidogrel, rivaroxaban) vs. metoprolol |
| Target Population | Patients aged 18 to 64 years with migraine and patent foramen ovale |
| Care Setting | Multicenter, randomized clinical trial |
Key Highlights
- Rivaroxaban showed higher responder rates compared to metoprolol, aspirin, and clopidogrel.
- 62% of patients on metoprolol achieved at least a 50% reduction in migraine days.
- No major bleeding events occurred during the trial.
- Complete migraine cessation was more common in patients receiving rivaroxaban.
- The study was conducted across 39 centers in China.
Guideline-Based Recommendations
Diagnosis
- Migraine diagnoses verified by site neurologists according to International Classification of Headache Disorders, third edition criteria.
Management
- Consideration of aspirin, clopidogrel, and rivaroxaban as noninferior to metoprolol for migraine prevention.
Monitoring & Follow-up
- Monitor for adverse events, particularly in patients receiving rivaroxaban.
Risks
- One serious adverse event related to rivaroxaban involved corpus luteum rupture with pelvic hemorrhage.
Patient & Prescribing Data
Patients with migraine and echocardiography-confirmed patent foramen ovale.
Rivaroxaban may help identify patients with a more embolic driven migraine phenotype.
Clinical Best Practices
- Maintain awareness of the limitations of the study, including its open-label design and short treatment duration.
- Use caution in interpreting the findings as evidence to replace first-line preventive treatments.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
